In particular, in-vitro exposure of CLL cells to the small non-genotoxic molecule Nutlin-3, a potent and selective inhibitor of TP53/MDM2 interaction, has been proposed to evaluate TP53 functionality [21,26,30]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.